Abstract

Human serum albumin (HSA) is the frontline antioxidant protein in blood with established anti-inflammatory and anticoagulation functions. Here we report that COVID-19-induced oxidative stress inflicts structural damages to HSA and is linked with mortality outcome in critically ill patients. We recruited 39 patients who were followed up for a median of 12.5 days (1-35 days), among them 23 had died. Analyzing blood samples from patients and healthy individuals (n=11), we provide evidence that neutrophils are major sources of oxidative stress in blood and that hydrogen peroxide is highly accumulated in plasmas of non-survivors. We then analyzed electron paramagnetic resonance (EPR) spectra of spin labelled fatty acids (SLFA) bound with HSA in whole blood of control, survivor, and non-survivor subjects (n=10-11). Non-survivor' HSA showed dramatically reduced protein packing order parameter, faster SLFA correlational rotational time, and smaller S/W ratio (strong-binding/weak-binding sites within HSA), all reflecting remarkably fluid protein microenvironments. Following loading/unloading of 16-DSA we show that transport function of HSA maybe impaired in severe patients. Stratified at the means, Kaplan–Meier survival analysis indicated that lower values of S/W ratio and accumulated H2O2 in plasma significantly predicted in-hospital mortality (S/W≤0.15, 81.8% (18/22) vs. S/W>0.15, 18.2% (4/22), p=0.023; plasma [H2O2]>8.6 mM, 65.2% (15/23) vs. 34.8% (8/23), p=0.043). When we combined these two parameters as the ratio ((S/W)/[H2O2]) to derive a risk score, the resultant risk score lower than the mean (< 0.019) predicted mortality with high fidelity (95.5% (21/22) vs. 4.5% (1/22), logrank c2 = 12.1, p=4.9x10-4). The derived parameters may provide a surrogate marker to assess new candidates for COVID-19 treatments targeting HSA replacements and/or oxidative stress.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Raw data collected and used to produce all figures and tables are available on Dyrad (https://doi.org/10.5061/dryad.cnp5hqc4q).

The following data sets were generated

Article and author information

Author details

  1. Mohamed A Badawy

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1691-0167
  2. Basma A Yasseen

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  3. Riem M El-Messiery

    Faculty of Medicine, Cairo University, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  4. Engy A Abdel-Rahman

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  5. Aya A Elkhodiry

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5684-0242
  6. Azza G Kamel

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  7. Hajar El-sayed

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  8. Asmaa M Shedra

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  9. Rehab Hamdy

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  10. Mona Zidan

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  11. Diaa Al-Raawi

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  12. Mahmoud Hammad

    Pediatric Oncology Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1677-0360
  13. Nahla Elsharkawy

    Clinical pathology department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  14. Mohamed El Ansary

    Department of Intensive Care, Faculty of Medicine, Cairo University, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  15. Ahmed Al-Halfawy

    Department of Pulmonary Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  16. Alaa Elhadad

    Pediatric Oncology Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  17. Ashraf Hatem

    Department of Chest Diseases, Faculty of Medicine, Cairo University, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  18. Sherif Abouelnaga

    Pediatric Oncology Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  19. Laura L Dugan

    Division of Geriatric Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, United States
    Competing interests
    The authors declare that no competing interests exist.
  20. Sameh Saad Ali

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    For correspondence
    sameh.ali@57357.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0339-6106

Funding

The Association of Friends of the National Cancer Institute (COVID-SA)

  • Sameh Saad Ali

The Children's Cancer Hospital Egypt (SA-Start up)

  • Sameh Saad Ali

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Written informed consents were obtained from participants in accordance with the principles of the Declaration of Helsinki. For COVID-19 and control blood/plasma collection, Children's Cancer Hospital's Institutional Review Board (IRB) has evaluated the study design and protocol, IRB number 31-2020 issued on July 6, 2020.

Copyright

© 2021, Badawy et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,858
    views
  • 209
    downloads
  • 32
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mohamed A Badawy
  2. Basma A Yasseen
  3. Riem M El-Messiery
  4. Engy A Abdel-Rahman
  5. Aya A Elkhodiry
  6. Azza G Kamel
  7. Hajar El-sayed
  8. Asmaa M Shedra
  9. Rehab Hamdy
  10. Mona Zidan
  11. Diaa Al-Raawi
  12. Mahmoud Hammad
  13. Nahla Elsharkawy
  14. Mohamed El Ansary
  15. Ahmed Al-Halfawy
  16. Alaa Elhadad
  17. Ashraf Hatem
  18. Sherif Abouelnaga
  19. Laura L Dugan
  20. Sameh Saad Ali
(2021)
Neutrophil-mediated oxidative stress and albumin structural damage predict COVID-19-associated mortality
eLife 10:e69417.
https://doi.org/10.7554/eLife.69417

Share this article

https://doi.org/10.7554/eLife.69417

Further reading

    1. Immunology and Inflammation
    Zhiyan Wang, Nore Ojogun ... Mingfang Lu
    Research Article

    The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been increasing worldwide. Since gut-derived bacterial lipopolysaccharides (LPS) can travel via the portal vein to the liver and play an important role in producing hepatic pathology, it seemed possible that (1) LPS stimulates hepatic cells to accumulate lipid, and (2) inactivating LPS can be preventive. Acyloxyacyl hydrolase (AOAH), the eukaryotic lipase that inactivates LPS and oxidized phospholipids, is produced in the intestine, liver, and other organs. We fed mice either normal chow or a high-fat diet for 28 weeks and found that Aoah-/- mice accumulated more hepatic lipid than did Aoah+/+ mice. In young mice, before increased hepatic fat accumulation was observed, Aoah-/- mouse livers increased their abundance of sterol regulatory element-binding protein 1, and the expression of its target genes that promote fatty acid synthesis. Aoah-/- mice also increased hepatic expression of Cd36 and Fabp3, which mediate fatty acid uptake, and decreased expression of fatty acid-oxidation-related genes Acot2 and Ppara. Our results provide evidence that increasing AOAH abundance in the gut, bloodstream, and/or liver may be an effective strategy for preventing or treating MASLD.

    1. Cell Biology
    2. Immunology and Inflammation
    Alejandro Rosell, Agata Adelajda Krygowska ... Esther Castellano Sanchez
    Research Article

    Macrophages are crucial in the body’s inflammatory response, with tightly regulated functions for optimal immune system performance. Our study reveals that the RAS–p110α signalling pathway, known for its involvement in various biological processes and tumourigenesis, regulates two vital aspects of the inflammatory response in macrophages: the initial monocyte movement and later-stage lysosomal function. Disrupting this pathway, either in a mouse model or through drug intervention, hampers the inflammatory response, leading to delayed resolution and the development of more severe acute inflammatory reactions in live models. This discovery uncovers a previously unknown role of the p110α isoform in immune regulation within macrophages, offering insight into the complex mechanisms governing their function during inflammation and opening new avenues for modulating inflammatory responses.